Status:
AVAILABLE
Expanded Access to Tipifarnib
Lead Sponsor:
Kura Oncology, Inc.
Conditions:
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Eligibility:
All Genders
18+ years
Brief Summary
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party conta...
Eligibility Criteria
Inclusion
- Inclusion/Exclusion Criteria:
- Diagnosed with HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL).
- Adult, ages 18+.
- Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
- Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
- Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04809233
Last Update
June 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.